Reviewing the Potential of Psychedelics for the Treatment of PTSD
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have also pointed out a potential of use of MDMA assisted psychotherapy as a minimal risk therapeutic method that works by reducing fear response to traumatic memories, while enhancing introspection and increasing interpersonal trust, which improves the patient-therapist relationship and so, the effectiveness of the therapy (Krediet et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To our knowledge, MDMA treatment efficacy is so far mainly assessed in PTSD patients, indicating moderate to large effects (Krediet et al., 2020;Bahji et al., 2020).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Krediet et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine has also been studied because of the rapid antidepressant properties that it exhibits (Krediet et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · cited 3×
“Integrated within a psychotherapeutic treatment, 2 to 3 sessions with MDMA have shown the ability to induce significant and sustained reductions in PTSD symptoms (Mithoefer et al., 2019).”
BackgroundMethodRetractedAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 1×
“pain relief, multiple sclerosis and epilepsy) have been growing again (Whiting et al., 2015; Haney and Hill, 2018).”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“Psilocybin has been studied for the treatment of depression (Carhart-Harris et al., 2016, 2017), tobacco and alcohol addiction (Johnson et al., 2014, 2017; Bogenschutz et al., 2015, 2018), obsessive-compulsive disorder (Moreno et al., 2006), and depression and anxiety in patients with…”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Research works printed but not linked: 5
- Gasser P (1996) Die psycholytische Psychotherapie in der Schweiz von 1988–1993. Schweiz Arch Neurol Psychiatr 147: 59– 65
- Grof S (1980) LSD psychotherapy. Pomona, CA: Hunter House.
- Ossebaard H, Maalsté N (1999) The bastiaans method of drug-assisted psychotherapy. In: MAPS Bulletin 9: 3– 9.
- Passie T (1997) Psycholytic and psychedelic therapy research 1931–1995: a complete international bibliography. Hannover, Germany: Laurentius Publ.
- Passie T (2012) Healing with entactogens: therapist and patient perspectives on MDMA-assisted group psychotherapy. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies (MAPS).
Cited by
Items 101–200 of 258
Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi
Bottemanne, H., Baldacci, A., Muller, C., Boyreau, A., & Claret, A. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.011 · Cited by 13
Methamphetamine and MDMA Neurotoxicity: Biochemical and Molecular Mechanisms
Bisagno, V., & Cadet, J. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_80-1 · Cited by 9
Herpers, J., Maximets, N., van Dongen, N. N. N., Zijlmans, J., & Vermetten, E. H. G. J. M. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2024.2378651 · Cited by 9
Self-citationThaoboonruang, N., Lohitnavy, O., Ya, K., & Lohitnavy, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-98202-w · Cited by 8
Simon, G., Gal-Birman, M., Tadmor, N., Halperin, D., & Ben‐Zion, Z. (2025) · European Journal of Psychotraumatology · doi:10.1080/20008066.2025.2582303 · Cited by 7
Wizła, M., Kraus, S. W., & Lewczuk, K. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152303 · Cited by 9
Rudzki, S. J. (2022) · Military Medicine · doi:10.1093/milmed/usac095 · Cited by 8
Psychedelic intimacy: Altered states of consciousness in romantic relationships
Neubert, J. J., Anderson, K., & Mason, N. L. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00319 · Cited by 12
Koweszko, T., de Barbaro, B., Izydorczyk, B., Mastalerz–Migas, A., Samochowiec, J., Szulc, A., Kowalska, A., Wachowska, K., & Gałecki, P. (2023) · Psychiatria Polska · doi:10.12740/pp/166172 · Cited by 7
Psychedelics, attachment, and enculturation dynamics: Prospects and challenges
Cassidy, E. K., Dupuis, D., Timmermann, C., & Granqvist, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00459 · Cited by 8
Blest‐Hopley, G., Pasculli, G., Ruffell, S., Tsang, W., Olateju, E., Pate, K. M., Kettner, H., Roseman, L., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1594307 · Cited by 8
Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy
Khan, F. A., Pandupuspitasari, N. S., Tencomnao, T., & Chuchawankul, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120882 · Cited by 8
Psychedelika in der Psychiatrie – Entwicklungen und die Stellung in Deutschland
Herwig, U., Mertens, L. J., Rosal, S. P., Koller, G., Jungaberle, A., Borgwardt, S., & Gründer, G. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1981-3152 · Cited by 7
Butler, M., Seynaeve, M., Bradley‐Westguard, A., Bao, J., Crawshaw, A. A., Pick, S., Edwards, M. J., Nicholson, T. R., & Rucker, J. (2022) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.21080213 · Cited by 7
Borisov, N. M., Ilnytskyy, Y., Byeon, B., Kovalchuk, O., & Kovalchuk, I. (2023) · Psychoactives · doi:10.3390/psychoactives2020007 · Cited by 6
Stocker, K., Hartmann, M., Reissmann, S., Kist, A., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.916641 · Cited by 7
Myers, M. G., & Toal, C. B. (1995) · PubMed · Cited by 7
Janssen‐Aguilar, R., Meshkat, S., Al-Shamali, H. F., Perivolaris, A., Swainson, J., Zhang, Y., Greenshaw, A. J., Burback, L., Winkler, O., Phillips, J. L., et al. (2025) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2025.241027 · Cited by 9
Self-citationMultimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain
Frautschi, P. C., Singh, A. P., Stowe, N. A., & Yu, J. J. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8118 · Cited by 5
On the social epistemology of psychedelic experience
Pedersen, M. M., & Steglich‐Petersen, A. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2369685 · Cited by 10
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Song, H., Xia, L.-L., Ma, Y., Jiao, D., Chen, S., Wang, L., Wang, W., Song, P., Mu, L., Li, L., et al. (2023) · Medical Science Monitor · doi:10.12659/msm.939485 · Cited by 9
Investigations on Rho/ROCK signaling in post-traumatic stress disorder-like behavior in mice
Sree, A. B., Hanifa, M., & Bali, A. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114347 · Cited by 5
Post-traumatic Stress Disorder
Hudak, R., & Gannon, J. M. (2022) · Current clinical practice · doi:10.1007/978-3-030-98709-1_7 · Cited by 6
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review
Wong, S., Jones, B. D. M., Thiyagarajah, M. T., Sabbah, S. G., Thompson, C. W., Solmi, M., Umer, M., Zrenner, C., Voineskos, D., Rosenblat, J. D., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251384513 · Cited by 5
Modlin, N. L., Williamson, V., Goodwin, G. M., Malievskaia, E., Atli, M., Elek, Z., Gaillard, A., Koelpin, D., Cleare, A. J., Agrawal, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103692 · Cited by 5
Feasibility of a Hypnosis Intervention for a Mystical Experience
Corlett, C. E., Alldredge, C. T., & Elkins, G. R. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2491352 · Cited by 5
Ilyin, N. P., Nabiullin, A. D., Kozlova, A. D., Kupriyanova, O. V., Shevyrin, V. A., Gloriozova, T. A., Filimonov, D. A., Lagunin, A. A., Galstyan, D. S., Kolesnikova, T. O., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00017 · Cited by 5
Griffin, C., & Knight, A. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00333 · Cited by 6
MDMA – hopes and fears associated with therapeutic use in mental disorders
Kozera, K., Cichoń, L., Wilczyński, K. M., & Janas-Kozik, M. H. (2020) · Pharmacotherapy in Psychiatry and Neurology · doi:10.33450/fpn.2020.10.002 · Cited by 5
Mendive, F. M., Giovannetti, C., & Arce, S. G. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2264466 · Cited by 7
Formoso, K. A. (2023) · Consciousness Spirituality & Transpersonal Psychology · doi:10.53074/cstp.2023.63 · Cited by 3
Sowndharya, M., Joga, R., Gandhi, K., Vijay, G. K., Waikar, S., Yerram, S., Raghuvanshi, R. S., & Srivastava, S. K. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00806-x · Cited by 3
Modlin, N. L., Williamson, V., Maggio, C., Stubley, J., Kirlić, N., Cleare, A. J., & Rucker, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251342319 · Cited by 3
Du, X., Liu, J., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03291-8 · Cited by 4
Ramaekers, J. G., Kuypers, K. P. C., & Vollenweider, F. X. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03602-7 · Cited by 3
Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study
Véliz‐García, Ó., & Domic‐Siede, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-74590-3 · Cited by 6
Tiedge, C. W., Valido, A., Rivas‐Koehl, M., Garcia, B. A., Robinson, L. E., Clements, G., & Espelage, D. L. (2025) · Prevention Science · doi:10.1007/s11121-025-01783-1 · Cited by 3
Biba, B.-J., & O’Shea, B. A. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2511750 · Cited by 4
The methanol and ethanol solvates of 4-glutarato-N,N-diisopropyltryptamine
Naeem, M., Bauer, B. E., Chadeayne, A. R., Golen, J. A., & Manke, D. R. (2022) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989022009094 · Cited by 3
Emmerich, N. (2024) · Neuroethics · doi:10.1007/s12152-024-09571-4 · Cited by 3
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg005 · Cited by 3
Fearful symmetry in altered states: a bi-logic account of psychedelic action
Goldreich, M. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1632923 · Cited by 2
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Soylemez, K. K., de Boo, E. M., Susuzlu, A., & Lusher, J. M. (2025) · Psychoactives · doi:10.3390/psychoactives4030031 · Cited by 2
The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry
Soylemez, K. K., de Boo, E. M., Susuzlu, A., & Lusher, J. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100450 · Cited by 4
Brown, R. E., Lissemore, J. I., Shinozuka, K., Coetzee, J. P., Faerman, A., Olash, C., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120722 · Cited by 4
Lima, G., Soares, C., Teixeira, M., Pais, M. L., Cabral, C., Rijo, P. M., & Castelo-Branco, M. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-31431-1 · Cited by 2
Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study
Dellanoce, F. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1617428 · Cited by 2
Varela, Y. M., Tavares, V. D. D. O., Delgado, L. M., de Faria, H. A. T., Menezes, L. Q., Almeida, R. M., Agrícola, P. M. D., de Carvalho, B. S., Bienemann, B., Falchi-Carvalho, M., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02188-5 · Cited by 1
Not a Standalone Treatment: Considerations for Psychedelic‐Assisted Therapy
Murphy, S., Stewart, E., Winship, J. R., Kampel, L., Stiel, B., & Ellis, J. (2026) · Brain and Behavior · doi:10.1002/brb3.71280 · Cited by 2
The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy
Heilman, J. (2023) · Journal of Scientific Exploration · doi:10.31275/20222633 · Cited by 7
Skinner, A., & Challis, S. (2023) · Cambridge Archaeological Journal · doi:10.1017/s0959774323000148 · Cited by 2
Development of the Japanese version of the Ego‐Dissolution Inventory (EDI)
Kusudo, K., Tani, H., Yonezawa, K., Nakajima, S., Nour, M. M., Carhart-Harris, R. L., & Uchida, H. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12419 · Cited by 1
Mozaffari, S., Delāvar, A., & Dortāj, F. (2023) · doi:10.61838/kman.jayps.4.2.4 · Cited by 2
Aghaei, A. M., Weleff, J., Martins, B. S., Ing, K., Fontenele, R., Barnett, B. S., Anand, A., & Nia, A. B. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00574-y · Cited by 2
Neurochemical characterization of 5-HT 2A R partial agonists with simultaneous PET-MRI
Bagdasarian, F. A., Larsen, K., Hong, D., Fisher, P. M., Mandeville, J. B., Sander, C. Y. M., Wey, H., & Hansen, H. D. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241302937 · Cited by 4
Singh, A. N. A., & de Assis, G. L. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00368-7 · Cited by 3
Psychedelics - A Cure for Sexual Trauma or a Risk Factor in Recreational and Treatment Settings?
Struble, C. A. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00372-x · Cited by 2
McGovern, H. T., Wellman, N., Hutchinson, B. T., Oestreich, L., Cooper, S., Fonzo, G. A., & Doss, M. K. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07163-z · Cited by 2
Timchenko, Y., Lyubinets, O. V., Oliinyk, P., Chaplyk, V. V., & Olіinyk, S. (2022) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2022.3.253119 · Cited by 4
Bourgault, Z., Ibrahim, C., Foll, B. L., & Hassan, A. N. (2022) · Journal of Traumatic Stress · doi:10.1002/jts.22879 · Cited by 4
Methamphetamine and MDMA Neurotoxicity: Biochemical and Molecular Mechanisms
Bisagno, V., & Cadet, J. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_80 · Cited by 2
da Silva, J. R. M. Q., & Mendonça, M. A. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i8.11098 · Cited by 2
Sentidos y vivencias relacionados con el uso recreativo de MDMA (Éxtasis)
Browarsk, L. A., & Fernández, J. E. (2023) · Psicología Conocimiento y Sociedad · doi:10.26864/pcs.v13.n1.1 · Cited by 2
Zaso, M. J., Fetkenhour, L. M., Park, Y., Simpson, T. L., Chung, T. A., Colder, C. R., Dvorak, R. D., & Read, J. P. (2024) · Traumatology An International Journal · doi:10.1037/trm0000535 · Cited by 1
Asimakopoulou, E., Theodosis‐Nobelos, P., & Triantis, C. (2024) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000139 · Cited by 2
Aburşu, H., Hesapçıoğlu, S. T., & Ceylan, M. F. (2024) · Qatar medical journal · doi:10.5339/qmj.2024.69 · Cited by 1
Toward a definition of treatment-resistant posttraumatic stress disorder: A systematic review
Al-Shamali, H. F., Meshkat, S., Janssen‐Aguilar, R., Uthayakumar, H., Burback, L., Winkler, O., Zhang, Y., Greenshaw, A. J., Enns, M. W., Nicholson, A. A., et al. (2025) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2025-0015 · Cited by 4
Self-citationFacing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors
Simon, G., Gal-Birman, M., Tadmor, N., & Halperin, D. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251372508 · Cited by 3
Dleštíková, T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105067 · Cited by 2
Tsang, V. W. L., Jones, T., Tsoi, S., Gorsuch, L., Dunn, R., & Schütz, C. G. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100009 · Cited by 1
The Art of Trafficking: How Politics Shape Narco-Strategies and Violence in Central America
Blume, L. R. (2025) · doi:10.1093/9780197818220.001.0001 · Cited by 3
Shende, P. A., Joga, R., Yerram, S., Gandhi, K., Sowndharya, M., & Srivastava, S. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10486-1 · Cited by 1
Robinson, J., Wallace, N., Cassidy, E. K., Lake, S., & Lucas, P. (2026) · Contemporary Drug Problems · doi:10.1177/00914509261444382 · Cited by 1
Ovies, D. H. (2021) · Perspectiva geográfica · doi:10.19053/01233769.12400 · Cited by 3
Hammel, R. L., Gulliver, B. J., Sukich, S. N., & Abraham, S. (2022) · International Journal of Science and Research Methodology · doi:10.25166/ijsrm/2022.20.3.2 · Cited by 2
Fontes, E. V. B., Porto, C. P. S., Neto, J. P. D. A., de Campos, V. A. M., de Oliveira, L. C., & Carvalho, L. F. C. (2022) · Research Society and Development · doi:10.33448/rsd-v11i9.31389 · Cited by 1
UC Berkeley Students’ Psychedelic Experiences: A Qualitative Analysis
Earp, D. (2023) · Berkeley Undergraduate Journal · doi:10.5070/b336161162 · Cited by 1
Novel Mechanisms and Interventions for PTSD
(2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021010 · Cited by 1
Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change
Omelchenko, N., & Kurapov, A. (2023) · Bulletin of Taras Shevchenko National University of Kyiv Psychology · doi:10.17721/bpsy.2023.1(17).8 · Cited by 1
Approaches towards Anxiety due to Post Traumatic Stress Disorder : A Review
Akhtar, U., Wankhade, A. M., Dhokane, Y. P., & Akhtar, S. (2023) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2023.00053 · Cited by 2
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Ghosh, P., & Sur, D. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822258502231120074036 · Cited by 1
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Ashraf, N. (2024) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.21.02.935 · Cited by 1
Kozhyna, H. M., & Sukharieva, V. (2025) · Ukrains kyi Visnyk Psykhonevrolohii · doi:10.36927/2079-0325-v33-is1-2025-5 · Cited by 2
Burdziak, K. (2021) · Acta Iuris Stetinensis · doi:10.18276/ais.2021.35-01 · Cited by 1
Posttraumatische stressstoornis
van Schagen, A. M., & Vermetten, E. H. G. J. M. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2524-5_13 · Cited by 1
Self-citationWillingness to participate in entheogen use research in naturalistic settings
Kirk, R. D., Uhley, O. M., Lehfeldt, P., Shields, C. M., Garretson, M., Collins, A., Wahbeh, H., & Dahmer, S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00238 · Cited by 3
Mozaffari, S., Delāvar, A., & Dortāj, F. (2023) · journal of Adolescent and Youth Psychological Studies · doi:10.52547/jspnay.4.2.32 · Cited by 1
Le concept de traumatisme et ses conséquences théoriques et cliniques
Fossati, P. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023005 · Cited by 2
Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)Preprint
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzøe, D., Douglass, H. M., Kettner, H., & Carhart-Harris, R. L. (2021) · doi:10.31234/osf.io/8vks6 · Cited by 1
Kelley, D. P., Venable, K. E., Billac, G. B., Destouni, A., Ebenezer, P. J., Stadler, K., Nichols, C. D., Barker, S. A., & Francis, J. (2021) · Research Square · doi:10.21203/rs.3.rs-602961/v1 · Cited by 1
Kelley, D. P. (2022) · Louisiana State University · doi:10.31390/gradschool_dissertations.5761 · Cited by 1
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
Lutyens, D. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.21904854 · Cited by 3
Therapeutic dissociation: From non-ordinary states to psychological transformationPreprint
Clingo, J. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ypr7w · Cited by 1
Bell, A. K., Watt, B. R., Flores, A. L., Rodriguez, S. R., Smith, D. T., & Stauffer, C. S. (2025) · Research Square · doi:10.21203/rs.3.rs-5908748/v1 · Cited by 2
Bredenberg, C., Normandin, F., Richards, B. A., & Lajoie, G. (2026) · eLife · doi:10.7554/elife.105968 · Cited by 3
Psychedelics in Mental Health: Opportunities and Challenges
Oestreich, L., & Rieser, N. M. (2026) · Brain and Behavior · doi:10.1002/brb3.71574 · Cited by 1
The Role(s) of Psychopharmacology in the Treatment of PTSD
Baig, M. R., & Roache, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00150-x · Cited by 1
Lian, Y. (2022) · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research · doi:10.2991/assehr.k.220110.184
Abraham, C. (2022) · Journal of Psychiatry Spectrum · doi:10.4103/jopsys.jopsys_13_21
Metadata
- Authors
- Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E.
- Affiliations
- Leiden University Medical Center (NL)
- University Medical Center Groningen (NL)
- ARQ National Psychotrauma Center, Diemen, The Netherlands
- Goethe University Frankfurt (DE)
- Corresponding author
- Vermetten, Eric
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-14
- Volume
- 23
- Issue
- 6
- Pages
- 385-400
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7311646
- OpenAlex
- W3011668650
- Cited by
- 260
- References
- 167
- Citations by year
- 2026: 21 · 2025: 62 · 2024: 54 · 2023: 43 · 2022: 44 · 2021: 24 · 2020: 11
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- Universiteit Leiden
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- post-traumatic stress disorder, psychedelics, MDMA, ketamine, psilocybin, LSD, cannabinoids, psychedelic-assisted psychotherapy, adjunctive therapy, psychiatric drug development
- MeSH terms
- Brain, Hallucinogens, Humans, Stress Disorders, Post-Traumatic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.